Home
/
Dare Bioscience, Inc.
/
Financials
/
Quarterly
Dare Bioscience, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Dare Bioscience, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2024
Sep 30, 2024
$41.7K
Nov 14, 2024
Q2
2024
Jun 30, 2024
$22.4K
Aug 12, 2024
Q1
2024
Mar 31, 2024
$9.3K
May 14, 2024
Q3
2024
Sep 30, 2023
$1.00M
Nov 14, 2024
Q2
2024
Jun 30, 2023
$0
Aug 12, 2024
Q1
2024
Mar 31, 2023
$0
May 14, 2024
Q3
2023
Sep 30, 2022
$0
Nov 9, 2023
Q2
2023
Jun 30, 2022
$10.00M
Aug 10, 2023
Q3
2022
Sep 30, 2021
$0
Nov 10, 2022
Q2
2022
Jun 30, 2021
$0
Aug 9, 2022
Q2
2017
Jun 30, 2017
$642.0K
Aug 14, 2017
Q1
2017
Mar 31, 2017
$1.19M
May 12, 2017
Q1
2015
Mar 31, 2015
$0
May 6, 2015
Q3
2015
Sep 30, 2014
$80.0K
Nov 16, 2015
Q2
2015
Jun 30, 2014
$33.0K
Aug 6, 2015
Q1
2015
Mar 31, 2014
$47.0K
May 6, 2015
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$2.3K
Nov 13, 2025
Q2
2025
Jun 30, 2025
$4.3K
Aug 14, 2025
Q1
2025
Mar 31, 2025
$25.4K
May 13, 2025
Q3
2025
Sep 30, 2024
$41.7K
Nov 13, 2025
Q2
2025
Jun 30, 2024
$22.4K
Aug 14, 2025
Q1
2025
Mar 31, 2024
$9.3K
May 13, 2025
Q3
2023
Sep 30, 2023
$1.00M
Nov 9, 2023
Q2
2024
Jun 30, 2023
$0
Aug 12, 2024
Q1
2024
Mar 31, 2023
$0
May 14, 2024
Q3
2023
Sep 30, 2022
$0
Nov 9, 2023
Q2
2023
Jun 30, 2022
$10.00M
Aug 10, 2023
Q3
2022
Sep 30, 2021
$0
Nov 10, 2022
Q2
2022
Jun 30, 2021
$0
Aug 9, 2022
Q2
2020
Apr 30, 2020
$731.0K
Aug 12, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($3.56M)
Nov 13, 2025
Q3
2025
Jun 30, 2025
($4.02M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($4.02M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($4.38M)
May 13, 2025
Q2
2025
Mar 31, 2025
($4.38M)
Aug 14, 2025
Q3
2025
Mar 31, 2025
($4.38M)
Nov 13, 2025
Q3
2025
Sep 30, 2024
($4.70M)
Nov 13, 2025
Q3
2025
Jun 30, 2024
$12.91M
Nov 13, 2025
Q2
2025
Jun 30, 2024
$12.91M
Aug 14, 2025
Q3
2025
Mar 31, 2024
($6.76M)
Nov 13, 2025
Q1
2025
Mar 31, 2024
($6.76M)
May 13, 2025
Q2
2025
Mar 31, 2024
($6.76M)
Aug 14, 2025
Q3
2024
Sep 30, 2023
($8.30M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($8.76M)
Aug 12, 2024
Q3
2024
Jun 30, 2023
($8.76M)
Nov 14, 2024
Q2
2024
Mar 31, 2023
($8.04M)
Aug 12, 2024
Q3
2024
Mar 31, 2023
($8.04M)
Nov 14, 2024
Q1
2024
Mar 31, 2023
($8.04M)
May 14, 2024
Q3
2023
Sep 30, 2022
($7.02M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
$414.0K
Aug 10, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($3.67M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($3.83M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($4.58M)
May 13, 2025
Q3
2025
Sep 30, 2024
($4.68M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($7.36M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($6.02M)
May 13, 2025
Q3
2024
Sep 30, 2023
($8.40M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($8.99M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($8.38M)
May 14, 2024
Q3
2023
Sep 30, 2022
($7.14M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
$384.3K
Aug 10, 2023
Q1
2023
Mar 31, 2022
($8.40M)
May 11, 2023
Q3
2022
Sep 30, 2021
($12.67M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($9.16M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($7.69M)
May 12, 2022
Q3
2021
Sep 30, 2020
($7.58M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($7.13M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($4.25M)
May 13, 2021
Q3
2020
Sep 30, 2019
($3.42M)
Nov 12, 2020
Q2
2020
Jun 30, 2019
($3.98M)
Aug 12, 2020